|1.||Ishii, Naoto: 5 articles (01/2015 - 04/2003)|
|2.||Sugamura, Kazuo: 4 articles (12/2010 - 04/2003)|
|3.||Tanaka, Yuetsu: 3 articles (01/2015 - 10/2010)|
|4.||Liu, Yong-Jun: 3 articles (03/2011 - 08/2007)|
|5.||Yagita, Hideo: 3 articles (02/2006 - 04/2003)|
|6.||Akiba, H: 3 articles (02/2001 - 01/2000)|
|7.||Yagita, H: 3 articles (02/2001 - 01/2000)|
|8.||Okumura, K: 3 articles (02/2001 - 01/2000)|
|9.||Kikuchi, Toshiaki: 2 articles (01/2015 - 05/2004)|
|10.||Wang, Qin: 2 articles (07/2014 - 05/2012)|
11/01/2007 - "Pathways involving the costimulatory molecule OX40 and OX40 ligand (OX40L) enhance tumor rejection. "
05/01/2004 - "OX40 ligand (OX40L), the ligand for OX40 on activated CD4+ T cells, has adjuvant properties for establishing effective T-cell immunity, a potent effector arm of the immune system against cancer. "
05/01/2004 - "Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts."
11/15/2010 - "We show that treatment of mice bearing well-established day 17 sarcomas with a novel OX40 ligand-Fc fusion protein (OX40L-Fc) resulted in tumor regression or dormancy in the majority of treated animals. "
04/15/2004 - "Using OX40-deficient CD8 cells specific for a defined Ag, and agonist and antagonist OX40 reagents, we show that OX40/OX40 ligand interactions can determine the extent of expansion of CD8 T cells during responses to conventional protein Ag and can provide sufficient signals to confer CTL-mediated protection against tumor growth. "
10/01/2010 - "To elucidate the immunological role for the costimulatory molecule OX40 against the early stage of HIV-1 infection, fresh peripheral blood mononuclear cells (PBMCs) from normal donors were stimulated with immobilized anti-CD3 monoclonal antibody (mAb) together with soluble anti-CD28 mAb for 24 h, infected with CCR5-tropic (R5) HIV-1, and then cocultured in the presence or absence of OX40 ligand (OX40L). "
08/01/2001 - "OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection."
03/15/2012 - "OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection."
11/01/2004 - "A panel of monoclonal antibodies specific for CD27 ligand (CD70), CD30 ligand (CD153), CD134 ligand (OX40L), and CD137 ligand (4-1BBL) were screened in vivo for their ability to affect the control of Mycobacterium avium infection in C57Bl/6 mice. "
|3.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
07/01/2013 - "To more precisely estimate the association between the tumor necrosis factor ligand superfamily member 4 (TNFSF4) gene polymorphisms and systemic lupus erythematosus (SLE) risk, we surveyed studies on the association of the TNFSF4 rs2205960, rs1234315, rs844644, and rs844648 polymorphisms with SLE. "
05/01/2012 - "The known tumor necrosis factor (ligand) superfamily, member 4 gene (TNFSF4) systemic lupus erythematosus (SLE) risk locus has been found to be associated with systemic sclerosis (SSc) in 2 studies, but with discrepancies between them for genotype-phenotype correlation. "
03/01/2010 - "The tumour necrosis factor ligand superfamily member 4 gene (TNFSF4, OX40L), which encodes for the T cell costimulatory molecule OX40 ligand, has been identified as a susceptibility gene for the development of systemic lupus erythematosus (SLE). "
12/01/2012 - "This study compares the expression levels of tumor necrosis factor ligand superfamily member 4 (TNFSF4) and TNF-R-associated factor 2 (TRAF2) mRNAs in peripheral blood mononuclear cells (PBMCs) of patients with systemic lupus erythematosus (SLE) against healthy controls. "
01/01/2013 - "This study aims to investigate the role of OX40 ligand (OX40L) in ocular inflammation via abrogation of retinal pigment epithelium (RPE)-mediated immunosuppression using an in vitro expression approach. "
05/15/2015 - "Basophil-associated OX40 ligand participates in the initiation of Th2 responses during airway inflammation."
12/01/2007 - "Blockade of interactions between OX40 on Th2 cells and OX40 ligand (OX40L) on TSLP-activated DCs using an OX40L-specific monoclonal antibody, inhibited Th2 cell-mediated immune responses in both mouse and nonhuman primate models of allergic inflammation. "
02/01/2015 - "Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligand expression."
10/15/2010 - "OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis."
|5.||Asthma (Bronchial Asthma)
06/01/2006 - "This study was conducted to evaluate the role of another costimulatory pathway OX40/OX40 ligand (L) in the pathogenesis of allergic asthma in BALB/c mice. "
05/15/2015 - "Here, we found for the first time that in a mouse model of allergic asthma basophils highly expressed OX40 ligand (OX40L) after activation. "
08/01/2014 - "OX40 ligand: a potential costimulatory molecule in atopic asthma."
07/01/2014 - "Immunohistochemistry assay showed that OX40 and OX40L protein levels were higher in asthma group than those in control group (all P<0.05). "
07/01/2014 - "To investigate whether the expression of OX40/OX40 ligand (OX40L) was upregulated in a murine model of asthma and their significance in the pathogenesis of asthma. "
|1.||Indicators and Reagents (Reagents)
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||4-1BB Ligand (4 1BB Ligand)
|5.||B-Cell Activating Factor
|6.||TNF Receptor-Associated Factor 2 (TRAF2)
|7.||Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
|9.||thymic stromal lymphopoietin